

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 August 2021 (26.08.2021)



(10) International Publication Number
WO 2021/165667 A1

(51) International Patent Classification:

A61K 39/12 (2006.01) C07K 14/165 (2006.01)
A61P 31/14 (2006.01) A61K 39/215 (2006.01)
C07K 14/005 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/GB2021/050383

(22) International Filing Date:

17 February 2021 (17.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2002166.3 17 February 2020 (17.02.2020) GB

(71) Applicant: VAXBIO LTD [GB/GB]; 95 Masons Road,
Oxford Oxfordshire OX3 8QN (GB).


(72) Inventors: GUPTA, Gaurav; 95 Masons Road, Heading-
ton, Oxford Oxfordshire OX3 8QN (GB). GLUECK, Rein-
hard; Via Portsalvo 34, CT 95041 Caltagirone (IT).

(74) Agent: GREGSON, Anna; Mathys & Squire LLP, The
Shard, 32 London Bridge Street, London SE1 9SG (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: 2019-NCOV (SARS-COV-2) VACCINE



(57) Abstract: The present invention relates to Coronavirus 2019-nCoV spike protein, polynucleotides encoding said spike protein, antibodies and vaccines for treatment or prevention of 2019-nCoV infection. One embodiment refers to isolated polynucleotide encoding a spike protein from 2019-nCoV having at least 90% identity with SEQ ID NO: 1, or a fragment thereof that has a common antigenic cross-reactivity with said spike protein, wherein said polynucleotide is optimised for recombinant expression. In a particular embodiment the polynucleotide is optimised for expression in a host cell selected from: (a) Escherichia coli; (b) yeast, preferably Komagataella or Saccharomyces; and/or (c) mammalian cells, preferably human cells.

[Continued on next page]

WO 2021/165667 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))